Pure Biologics SA(DE:PQB)
€0.22-0.01 (-2.19%)
DE:PQB
Pure Biologics SA financials statements
€0.22
At close:-0.01 (-2.19%)
Pure Biologics SA (PQB) Ratios
0 Followers
Pure Biologics SA Ratios
DE:PQB's free cash flow for Q1 2026 was zł-3.17M. For the 2026 fiscal year, DE:PQB's free cash flow was increased by zł0.00 and operating cash flow was zł-3.17M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.25 | 0.14 | 2.70 | 1.88 | 7.75 |
| Quick Ratio | 0.25 | 0.14 | 2.70 | 1.88 | 7.75 |
| Cash Ratio | 0.00 | 0.02 | 0.45 | 0.18 | 1.11 |
| Solvency Ratio | -0.51 | -1.25 | -1.43 | -1.62 | -1.32 |
| Operating Cash Flow Ratio | -0.33 | -0.70 | -2.91 | -1.35 | -4.33 |
| Short-Term Operating Cash Flow Coverage | -0.40 | -0.78 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | zł -14.27M | zł -13.35M | zł 755.00K | zł 9.46M | zł 35.31M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 3.24 | 6.00 | 0.57 | 0.09 | 0.07 |
| Debt-to-Equity Ratio | -1.13 | -1.07 | 6.83 | 0.16 | 0.08 |
| Debt-to-Capital Ratio | 8.61 | 14.91 | 0.87 | 0.14 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.87 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.35 | -0.18 | 12.01 | 1.80 | 1.20 |
| Debt Service Coverage Ratio | -0.34 | -0.80 | -6.80 | -71.57 | -43.72 |
| Interest Coverage Ratio | -2.88 | -9.31 | -8.27 | -74.86 | -46.18 |
| Debt to Market Cap | 0.91 | 0.16 | 0.32 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.70 | 3.00 | 5.26 | 1.44 | 1.50 |
| Net Debt to EBITDA | -2.59 | -1.12 | -0.36 | -0.03 | 0.36 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | -2709.47% | -816.77% | -1585.43% |
| EBIT Margin | 0.00% | 0.00% | -33537.89% | -3817.82% | -4542.52% |
| EBITDA Margin | 0.00% | 0.00% | -27449.47% | -3440.63% | -3392.91% |
| Operating Profit Margin | 0.00% | 0.00% | -33387.37% | -3720.39% | -4126.77% |
| Pretax Profit Margin | 0.00% | 0.00% | -37572.63% | -3867.52% | -4631.89% |
| Net Profit Margin | 0.00% | 0.00% | -37572.63% | -3983.69% | -5146.06% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -37572.63% | -3867.52% | -4631.89% |
| Net Income Per EBT | 125.34% | 147.36% | 100.00% | 103.00% | 111.10% |
| EBT Per EBIT | 123.76% | 106.51% | 112.54% | 103.95% | 112.24% |
| Return on Assets (ROA) | -198.79% | -829.49% | -156.98% | -79.89% | -27.70% |
| Return on Equity (ROE) | 69.41% | 148.18% | -1885.58% | -144.13% | -33.10% |
| Return on Capital Employed (ROCE) | 45.17% | 94.41% | -215.11% | -122.08% | -25.17% |
| Return on Invested Capital (ROIC) | -336.04% | -1311.76% | -213.86% | -115.79% | -24.52% |
| Return on Tangible Assets | -198.79% | -873.09% | -158.77% | -80.87% | -28.12% |
| Earnings Yield | -56.03% | -22.00% | -88.54% | -51.62% | -7.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.01 | 0.04 | 0.03 |
| Payables Turnover | 0.06 | 0.05 | 2.60 | 0.84 | 6.35 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.11 | 0.08 | 0.07 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.01 | 0.03 | 0.02 |
| Cash Conversion Cycle | -5823.93 | -6752.50 | 56511.39 | 7954.36 | 13292.34 |
| Days of Sales Outstanding | 0.00 | 0.00 | 56651.84 | 8389.49 | 13349.80 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 5823.93 | 6752.50 | 140.45 | 435.13 | 57.47 |
| Operating Cycle | 0.00 | 0.00 | 56651.84 | 8389.49 | 13349.80 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.28 | -2.11 | -7.29 | -7.83 | -10.82 |
| Free Cash Flow Per Share | -1.28 | -2.11 | -7.35 | -10.42 | -11.12 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -132.17 | -3.02 | -35.71 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -132.17 | -3.02 | -35.71 |
| Operating Cash Flow Coverage Ratio | -0.39 | -0.77 | -1.80 | -6.08 | -7.72 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -244.86 | -26.26 | -94.63 |
| Free Cash Flow Yield | -35.82% | -12.26% | -58.14% | -45.31% | -14.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.79 | -4.55 | -1.13 | -1.94 | -13.22 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 424.37 | 77.17 | 680.33 |
| Price-to-Book (P/B) Ratio | -1.24 | -6.73 | 21.30 | 2.79 | 4.38 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.79 | -8.16 | -1.72 | -2.21 | -6.99 |
| Price-to-Operating Cash Flow Ratio | -2.79 | -8.16 | -1.73 | -2.94 | -7.19 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.07 | 0.20 | -0.02 | 0.67 |
| Enterprise Value Multiple | -5.43 | -8.34 | -1.90 | -2.27 | -19.70 |
| Enterprise Value | 33.52M | 102.08M | 49.65M | 51.69M | 169.74M |
| EV to EBITDA | -5.43 | -8.34 | -1.90 | -2.27 | -19.70 |
| EV to Sales | 0.00 | 0.00 | 522.60 | 78.08 | 668.26 |
| EV to Free Cash Flow | -5.34 | -9.43 | -2.12 | -2.23 | -6.87 |
| EV to Operating Cash Flow | -5.34 | -9.43 | -2.13 | -2.97 | -7.06 |
| Tangible Book Value Per Share | -2.87 | -2.58 | 0.51 | 8.06 | 17.46 |
| Shareholders’ Equity Per Share | -2.87 | -2.55 | 0.59 | 8.24 | 17.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.03 | -0.11 |
| Revenue Per Share | 0.00 | 0.00 | 0.03 | 0.30 | 0.11 |
| Net Income Per Share | -1.99 | -3.78 | -11.19 | -11.87 | -5.88 |
| Tax Burden | 1.25 | 1.47 | 1.00 | 1.03 | 1.11 |
| Interest Burden | 1.24 | 1.07 | 1.12 | 1.01 | 1.02 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 35.93 | 81.02 |
| SG&A to Revenue | 0.00 | 0.00 | 68.83 | 12.13 | 14.95 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 13.71 | 6.67 | 10.97 |
| Income Quality | 0.80 | 0.56 | 0.65 | 0.68 | 2.04 |
Currency in PLN

